Bromodomain-containing protein 9 (BRD9) (BRD9)

Bromodomain-containing protein 9 (BRD9) is a key subunit of the non-canonical BAF (ncBAF) chromatin remodeling complex, which is essential for regulating gene expression and maintaining chromatin structure [5, 17]. As an epigenetic reader, BRD9 contains a single bromodomain that specifically recognizes and binds to acetylated lysine residues on histone tails, thereby recruiting transcriptional machinery to specific genomic sites [6, 7]. BRD9 has emerged as a critical therapeutic target in several aggressive cancers, particularly those with SWI/SNF complex alterations, such as synovial sarcoma (characterized by the SS18-SSX fusion) and SMARCB1-deficient malignant rhabdoid tumors [1, 3, 11]. In these contexts, BRD9 is required to sustain oncogenic transcriptional programs and promote tumor cell survival [5, 11]. Therapeutic interventions targeting BRD9 include the development of selective small-molecule inhibitors and targeted protein degraders (PROTACs), such as CFT8634 and FHD-609 [1, 4, 8]. These drugs aim to disrupt the ncBAF complex by either blocking the bromodomain's binding activity or inducing proteasomal degradation of the entire protein [1, 4, 8]. While clinical trials have demonstrated proof-of-mechanism for BRD9 degradation, challenges such as dose-limiting cardiac toxicities have been observed [8]. Additionally, the necessity for precise patient stratification based on biomarkers like SMARCB1 status or SS18-SSX fusion remains a significant hurdle in its therapeutic development [3, 8, 17]. Beyond oncology, BRD9 is also being investigated for its role in inflammatory conditions like rheumatoid arthritis [6, 9].

Other names

Bromodomain-containing protein 9PRO2185

Bromodomain inhibition and targeted protein degradation (PROTAC)